



### **Disclaimer**

The information contained in this document ("Presentation") has been prepared by Totally plc (the "Company"). The Company is a UK company quoted on AIM, a market operated by London Stock Exchange plc. This Presentation has not been verified nor has it been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA") and therefore it is being provided for information purposes only.

Allenby Capital Limited ("Allenby Capital"), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and joint broker to the Company. Canaccord Genuity Limited ("Canaccord"), which is authorised and regulated by the Financial Conduct Authority, is acting as joint broker to the Company. Accordingly, the recipients should note that Allenby Capital and Canaccord are neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Allenby Capital and Canaccord nor for providing advice in relation to the matters contained in this Presentation.

While the information contained herein has been prepared in good faith, neither the Company nor any of its directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

The views of the Company's management/directors and/or its partners set out in this document could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures here and investors should place no reliance on the Company's estimates cited in this document.

This Presentation may contain "forward-looking statements" that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, performance, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on

circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, Canada, Japan, the Republic of South Africa or the United States of America (each a "Restricted Territory"), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

## Agenda

## Results for 6 months ending 30 September 2022

- Overview, Wendy Lawrence, CEO
- Financial highlights, Lisa Barter, CFO
- Operational update, Wendy Lawrence, CEO



## Continued progress, well-positioned for current and future opportunities

### Continued growth in revenue and profit

Managing opportunities alongside challenges and growth

Delivered quality services to c.1.25 million patients

### **Growth opportunities for new business resuming**

Via tenders, framework agreements, service resilience services and contract extensions


## Financial highlights Lisa Barter, CFO

### Further growth in revenue and profit


Performance in line with management expectations for revenue and earnings.

- Revenue up 14.1% at £70.3 million (H1 2022: £61.6 million)
- EBITDA increased at £3.4 million (H1 2022: £3.3 million)
- Profit before tax of £1.0 million (H1 2022: £0.9 million).
- Cash at £7.4 million (31 March 2022: £15.3 million) reflecting impact of changes in working capital model and growth
- No debt; £5 million RCF in place
- Proposed interim dividend of 0.5p per share (H1 2022: 0.5p) to be paid in February 2023





Underlying EBITDA £3.4m +3.1%



# Operational update Wendy Lawrence, CEO

### **Operational highlights**

- Delivered services to approximately 1.25 million patients
- Extensions to 15 existing urgent care contracts amounting to c.£37 million
- Step in contract to deliver NHS 111 in Devon valued at up to £850,000
- Five-year contract extension awarded to EFP by Royal Mail, worth c.£2.5 million
- Pioneer awarded new contract and four contract extensions, collectively valued at approximately c.£9.5 million
- All CQC registerable services continued to be rated as GOOD



### **Continued operational progress**



- 15 contract extensions valued at c.£37 million
- Stepped in to support NHS 111 services in Devon – now continuing support until January 2023
- GOOD overall ratings received from CQC for three urgent treatment centres in London
- Services will provide millions of people with access to the healthcare they need during what could be another difficult winter



- Operating at pre-pandemic levels
- Continue to work with commissioners to identify ways in which we can contribute to the reduction of the current backlog of patients
- Seeing new opportunities presented by commissioners for physiotherapy services and dermatology services



- Demand for insourcing and outsourcing services continues to rise
- New one year contract valued at approximately £5 million
- Four contract extensions for insourcing and outsourcing valued at c. £4.5 million
- National AQP (Any Qualified Provider) status places Pioneer in an excellent position to support NHS with reduction of waiting lists
- Expect continued growth linked to Government waiting list commitment and independent sector support



- Five-year contract extension for the delivery of the Royal Mail's on-site gyms across 34 sites in the UK
- Three new contract wins including gym refurbishment/relaunch of existing wellbeing service for global video game giant Electronic Arts in the UK
- Extensive pipeline of new opportunities across the UK
- Additional services being provided as part of being within Totally including physiotherapy and access to health care professionals for employees

### Well-positioned for significant market opportunities

#### Scale of opportunity remains significant:

- Continuing increases in demand for urgent care services
- Record number of patients waiting to be treated
- Renewed focus on corporate wellbeing

#### Well-positioned to play a role in the healthcare recovery

- Proven that we can deliver quality patient care and maintain GOOD ratings on all CQC registered services whilst services are under pressure
- Invested significantly to ensure growth trajectory is underpinned with robust systems and processes, and ability to provide capacity to support service pressures
- Pioneer's well-established recruitment model somewhat protects it from the wider challenges of recruitment faced elsewhere
- Continue to seek out and identify new opportunities to drive efficiencies as part of our business-as-usual cost management processes

## **Totally**

Cardinal Square West 10 Nottingham Road Derby, DE1 3QT

